Known targets — ChEMBL curated mechanism
HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9
The experimentally established mechanism targets of Panobinostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 20/20 | 1.00 |
| ▸ | HDAC2 known ✓ | Q92769 | 12/20 | 1.00 |
| ▸ | HDAC3 known ✓ | O15379 | 12/20 | 1.00 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 5/20 | 1.00 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 5/20 | 1.00 |
| ▸ | HDAC4 known ✓ | P56524 | 4/20 | 1.00 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 3/20 | 1.00 |
| ▸ | HDAC10 known ✓ | Q969S8 | 3/20 | 1.00 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 3/20 | 1.00 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 3/20 | 1.00 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 3/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 8/20 | 1.00 |
| ▸ | TET3 | O43151 | 1/20 | 1.00 |
| ▸ | BRD4 | O60885 | 1/20 | 1.00 |
| ▸ | FOXO1 | Q12778 | 1/20 | 1.00 |
| ▸ | TET2 | Q6N021 | 1/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 1.00 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Panobinostat SCHEMBL22773814 | 1.00 | HDAC1 (1.00) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL164801 | 1.00 | HDAC1 (1.00) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL436875 | 0.99 | HDAC1 (0.98) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL20165843 | 0.99 | HDAC1 (0.98) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL30235437 | 0.93 | HDAC1 (0.87) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL29358399 | 0.93 | HDAC1 (0.87) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL2315056 | 0.93 | HDAC1 (0.87) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL2315067 | 0.93 | HDAC1 (0.87) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| SCHEMBL10036755 | 0.93 | HDAC1 (0.86) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL2316088 | 0.93 | HDAC1 (0.86) | HDAC1HDAC2HDAC3NCOR2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1788 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364089-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION | CERENO SCIENT AB (SE) | 2023-11-16 | — | — | US | claimed |
| US-11554123-B2 | Compositions and methods for reactivating latent HIV-1 infections | SAINT JOSEPH'S UNIVERSITY (US) | 2023-01-17 | — | — | US | claimed |
| US-20210340218-A1 | MONOCYTE MODULATION AND CONTROL OF TUMOR METASTASIS | LA JOLLA INST ALLERGY & IMMUNOLOGY (US) | 2021-11-04 | — | — | US | claimed |
| US-10813919-B2 | Use of histone deacetylase inhibitors for enhancing immunotherapies | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-10-27 | — | — | US | claimed |
| EP-3662903-A2 | COMBINATION THERAPIES | Novartis AG (CH) | 2020-06-10 | — | — | EP | claimed |
| US-20200016168-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT HIV-1 INFECTIONS | SAINT JOSEPH'S UNIVERSITY | 2020-01-16 | — | — | US | claimed |
| EP-3407913-A1 | USE OF HISTONE DEACETYLASE INHIBITORS FOR ENHANCING IMMUNOTHERAPIES | Indiana University Research & Technology Corporation (US) | 2018-12-05 | — | — | EP | claimed |
| US-20180312568-A1 | MONOCYTE MODULATION AND CONTROL OF TUMOR METASTASIS | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2018-11-01 | — | — | US | claimed |
| US-20180289670-A1 | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2018-10-11 | — | — | US | claimed |
| EP-3350313-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | Agency For Science, Technology And Research (A*star) (SG) | 2018-07-25 | — | — | EP | claimed |
| US-20050085507-A1 | p-phenylethenyl hydroxamates; anticarcinogenic, antitumor, antiproliferative agents; regulating p21 promoter; improved stability | SECURA BIO, INC. | 2005-04-21 | — | — | US | claimed |
| WO-2005013958-A1 | HISTONE DEACETYLASE INHIBITORS AS IMMUNOSUPPRESSANTS | NOVARTIS AG (CH) | 2005-02-17 | — | — | WO | claimed |
| US-20050032899-A1 | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | NOVARTIS AG (CH) | 2005-02-10 | — | — | US | claimed |
| US-6833384-B2 | E. g., N-Hydroxy-3-(4-(((2-(1H-indol-3-yl)-ethyl)amino)-amino)methyl)-phenyl)-2E-2 -propenamide; histone deacetylase inhibitors; antiproliferative agents; antitumor agents; anticarcinogenic agents | NOVARTIS AG (CH) | 2004-12-21 | — | — | US | claimed |
| EP-1456664-A1 | USE OF ALPHA-TUBULIN ACETYLATION LEVELS AS A BIOMARKER FOR PROTEIN DEACETYLASE INHIBITORS | Novartis AG (CH) | 2004-09-15 | — | — | EP | claimed |
| US-20040024067-A1 | Deacetylase inhibitors | ATHYRIUM OPPORTUNITIES III ACQUISITION LP | 2004-02-05 | — | — | US | claimed |
| EP-1318980-A2 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | Novartis AG (CH) | 2003-06-18 | — | — | EP | claimed |
| WO-2003048774-A1 | USE OF ALPHA-TUBULIN ACETYLATION LEVELS AS A BIOMARKER FOR PROTEIN DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2003-06-12 | — | — | WO | claimed |
| US-20030018062-A1 | Deacetylase inhibitors | SECURA BIO, INC. | 2003-01-23 | — | — | US | claimed |
| WO-2002022577-A2 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2002-03-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312568-A1 | MONOCYTE MODULATION AND CONTROL OF TUMOR METASTASIS | CD14, CX3CR1, CCR2 | HDAC1 1210/4885HDAC2 2604/4885HDAC3 853/4885 |
| US-20230364089-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION | HDAC3, HDAC1, HDAC5 | HDAC1 2/4885HDAC2 4/4885HDAC3 1/4885 |
| US-20210340218-A1 | MONOCYTE MODULATION AND CONTROL OF TUMOR METASTASIS | CD14, CX3CR1, CCR2 | HDAC1 1062/4885HDAC2 2508/4885HDAC3 851/4885 |
| US-20050085507-A1 | p-phenylethenyl hydroxamates; anticarcinogenic, antitumor, antiproliferative agents; regulating p21 promoter; improved stability | TP53, CDKN1A, HDAC1 | HDAC1 3/4885HDAC2 18/4885HDAC3 16/4885 |
| US-20040024067-A1 | Deacetylase inhibitors | HDAC1, HDAC3, HDAC6 | HDAC1 1/4885HDAC2 9/4885HDAC3 2/4885 |
| US-20050032899-A1 | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | HDAC2, HDAC9, HDAC1 | HDAC1 3/4885HDAC2 1/4885HDAC3 5/4885 |
| US-20030018062-A1 | Deacetylase inhibitors | HDAC1, HDAC3, HDAC6 | HDAC1 1/4885HDAC2 9/4885HDAC3 2/4885 |
| US-20180289670-A1 | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER | MCL1, BAD, LPXN | HDAC1 633/4885HDAC2 423/4885HDAC3 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.